Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it

Page 9 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to DysinsulinismCompletedNCT00847080Phase 4
• Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy SubjectsCompletedNCT00842556Phase 1
• Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyCompletedNCT00822211Phase 3
• Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 DiabetesCompletedNCT00821977Phase 2/3
• Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired PatientsCompletedNCT00818571Phase 1/2
• Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy IndividualsCompletedNCT00813228Phase 1
• Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of SaxagliptinCompletedNCT00770302Phase 1
• Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)CompletedNCT00770081Phase 3
• Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During RamadanTerminatedNCT00766441Phase 4
• Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)CompletedNCT00765830Phase 3
• Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes MellitusCompletedNCT00760344Phase 2
• How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.CompletedNCT00747383Not applicable
• Sitagliptin in Renal Transplant RecipientsCompletedNCT00740363Phase 4
• Bone Turnover in Type 2 Diabetes PatientsStatus unknownNCT00732121Phase 4
• Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)CompletedNCT00728351Phase 3
• Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic SyndromeCompletedNCT00721552Not applicable
• Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative StressStatus unknownNCT00699322Phase 4
• The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and InflammationStatus unknownNCT00696982Not applicable
• A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)CompletedNCT00696826Phase 1
• Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes MellitusCompletedNCT00690638Phase 3
• Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular AxisCompletedNCT00683735Phase 2/3
• Efficacy of SYR-472 in Subjects With Type 2 Diabetes MellitusCompletedNCT00653185Phase 2
• Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy SubjectsCompletedNCT00651105Phase 3
• Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial InfarctionCompletedNCT00650143Phase 2/3
• Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal InsufficiencyCompletedNCT00646542Phase 3
• An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)CompletedNCT00642798Phase 1
• Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 DiabetesTerminatedNCT00633997Phase 1/2
• Beta-cell Function in Glucose Abnormalities and Acute Myocardial InfarctionCompletedNCT00627744Phase 4
• Effect of PF-00734200 in Subjects With Type 2 DiabetesCompletedNCT00618007Phase 2
• Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal InsufficiencyCompletedNCT00616811Phase 3
• A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney FunctionCompletedNCT00596518Phase 1
• Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired PatientsCompletedNCT00572650Phase 1
• Pharmacokinetic Study of Vildagliptin in Patients With Renal ImpairmentCompletedNCT00567047Phase 1
• Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes MellitusCompletedNCT00551590Phase 1
• Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes MellitusCompletedNCT00532506Phase 2
• A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.CompletedNCT00502710Phase 2
• Effects of Sitagliptin on Gastric Emptying in Healthy SubjectsCompletedNCT00501657Phase 1
• Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT00494884Phase 3
• A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes MellitusStatus unknownNCT00482950Phase 2
• A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)CompletedNCT00481663Phase 2
• A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusCompletedNCT00477581Phase 4
• 12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With MetforminCompletedNCT00473525Phase 2
• A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus MetforminCompletedNCT00468039Phase 3
• Sitagliptin Treatment in Patients With Type 2 DM After Kidney TransplantCompletedNCT00466518Not applicable
• Sitagliptin in the ElderlyCompletedNCT00451113Phase 2
• Effect of Januvia on Beta Cell Function in Patients With Diabetes MellitusCompletedNCT00425490Phase 3
• Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese VolunteersCompletedNCT00419887Phase 1
• Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy VolunteersCompletedNCT00414947Phase 1
• Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin AloneCompletedNCT00396357Phase 3
• Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin AloneCompletedNCT00396227Phase 3
• Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With MetforminCompletedNCT00396071Phase 3
• Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 DiabetesCompletedNCT00390520Phase 3
• Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 DiabetesCompletedNCT00389415Phase 3
• Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)WithdrawnNCT00387972Phase 2/3
• Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 DiabetesCompletedNCT00383578Phase 3
• Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 DiabetesCompletedNCT00382096Phase 3
• Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 DiabetesCompletedNCT00380445Phase 3
• A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.CompletedNCT00380380Phase 3
• To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesCompletedNCT00368134Phase 3
• Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes MellitusCompletedNCT00363948Phase 3
• Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes MellitusCompletedNCT00363844Phase 3
• Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes MellitusCompletedNCT00363519Phase 3
• A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 DiabetesCompletedNCT00351832Phase 3
• A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 DiabetesCompletedNCT00351585Phase 3
• A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 DiabetesCompletedNCT00351546Phase 3
• A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 DiabetesCompletedNCT00351507Phase 3
• Long-Term Safety Study of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00325429Phase 3
• To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea MonotherapyCompletedNCT00325117Phase 3
• A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetesCompletedNCT00312130Phase 3
• A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild HyperglycemiaCompletedNCT00300287Phase 3
• A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 DiabetesCompletedNCT00260156Phase 3
• A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00238498Phase 2
• Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose ToleranceCompletedNCT00237250Phase 3
• Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00237237Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00138619Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00138606Phase 3
• Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%CompletedNCT00138593Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesCompletedNCT00138580Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00138567Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00138554Phase 3
• Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00138541Phase 3
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00138515Phase 3
• Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00120536Phase 3
• A Study of DPP-IV Inhibitor in Patients With Type 2 DiabetesCompletedNCT00111670Phase 2
• Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 DiabetesCompletedNCT00110240Phase 3
• Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00106340Phase 3
• Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00102466Phase 3
• Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 DiabetesCompletedNCT00102388Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00101803Phase 3
• Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild HyperglycemiaCompletedNCT00101712Phase 3
• Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%CompletedNCT00101673Phase 3
• A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 DiabetesCompletedNCT00099957Phase 2
• Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 DiabetesCompletedNCT00099944Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00099931Phase 3
• Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00099918Phase 3
• A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00099905Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00099892Phase 3
• Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 DiabetesCompletedNCT00099866Phase 3
• Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00099853Phase 3

← Dipeptidyl-Peptidase IV Inhibitors overview